Company intelligence / Profile preview
Verseau Therapeutics
Bedford, Massachusetts, United Statesverseautx.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Lead monoclonal antibody programs targeting PSGL‑1 and VSIG4 are advancing toward the clinic. Ex vivo studies with fresh human tumors show these candidates can be more effective than PD‑1 checkpoint blockade at stimulating a pro-inflammatory tumor microenvironment. No clinical trial results reported yet.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)siRNA therapeutics
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
No major pharma partnerships disclosed as of latest information.
Beyond the preview
Go deeper on Verseau Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Verseau Therapeutics.